The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species

Anti-Cancer Drugs

Volumn 16, Issue 1, 2005, Pages 93-99

  Wu, Xing ^a   Hasinoff, Brian B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Daunorubicin; Dexrazoxane; Doxorubicin; Free radicals; Iron; Reactive oxygen species; Type II DNA topoisomerase

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; LACTATE DEHYDROGENASE; OXYGEN RADICAL; RAZOXANE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARDIOTOXICITY; CATALYSIS; CELL GROWTH; CHELATION; CHO CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME RELEASE; GROWTH INHIBITION; HEART MUSCLE CELL; HEART PROTECTION; HYDROLYSIS; MUTATION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOVASCULAR AGENTS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; ENZYME INHIBITORS; IRON; MODELS, ANIMAL; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RAZOXANE; REACTIVE OXYGEN SPECIES;

EID: 12544255061     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200501000-00014     Document Type: Article

References (45)

1. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226:466-468.
2. Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, et al. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 1989; 49:5969-5978.
3. Corbett AH, Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 1993; 6:585-597.
4. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56:185-229.
5. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57:727-741.
6. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000; 207:77-86
7. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990; 47:219-231.
8. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, et al. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991; 51:4909-4916.
9. Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 1995; 50:953-958.
10. Hasinoff BB, Abram ME, Chee G-L, Huebner E, Byard EH, Barnabé N, et al. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells. J Pharmacol Exp Ther 2000; 295:474-483.
11. Fattman C, Allan WP, Hasinoff BB, Yalowich JC. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells. Biochem Pharmacol 1996; 52:635-642.
12. Hasinoff BB, Yalowich JC, Ling Y, Buss JL. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs 1996; 7:558-567
13. Hasinoff BB, Kuschak TI, Creighton AM, Fattman CL, Allan WP, Thampatty P, et al. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol 1997; 53: 1843-1853.
14. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJF. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1- yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 1993; 46:389-393.
15. Bachur NR, Gordon SL, Gee MV, Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 1979; 76:954-957.
16. Garner AP, Paine MJ, Rodriguez-Crespo I, Chinje EC, Ortiz DMP, Stratford U, et al. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res 1999; 59:1929-1934
17. Barnabe N, Zastre J, Venkataram S, Hasinoff BB. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Rad Biol Med 2002; 33:266-275.
18. 2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group. Biochim Biophys Acta 1986; 884:326-336.
19. Malisza KL, Hasinoff BB. Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch Biochem Biophys 1995; 321:51-60.
20. Gianni L, Corden BJ, Myers CE. The biochemical basis of anthracycline toxicity and anti-tumor activity. Rev Biochem Toxicol 1983; 5:1-82.
21. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 19:670-686.
22. Gianni L, Zweier JL, Levy A, Myers CE. Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen. J Biol Chem 1985; 260:6820-6826.
23. Hasinoff BB. Chemistry of dexrazoxane and analogues. Semin Oncol 1998; 25(suppl 10):3-9.
24. Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 1998; 25(suppl 10):43-47.
25. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998; 5:1-28.
26. Hasinoff BB. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J Pharm Sci 1994; 83:64-67.
27. Hasinoff BB. An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates. Int J Pharm 1994; 107:67-76.
28. Buss JL, Hasinoff BB. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Ag Actions 1993; 40:86-95.
29. Dawson KM. Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem Pharmacol 1975; 24:2249-2253.
30. Yalowich JC, Thampatty P, Allan WP, Chee G-L, Hasinoff BB. Acquired resistance to ICRF-187 (dexrazoxane) in a CHO cell line is associated with a point mutation in DNA topoisomerase IIα (topo II) and decreased drug-induced DNA-enzyme complexes. Proc Am Ass Cancer Res 1998; 39:375.
31. Classen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci USA 2003; 100:10629-10634.
32. Classen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci USA 2003; 100:14510.
33. Hasinoff BB, Schnabl KL, Marusak RA, Patel D, Huebner E. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol 2003; 3:89-99.
34. Hasinoff BB. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc Toxicol 2002; 2:111-118.
35. Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Rad Biol Med 2003; 35:1469-1479.
36. Hasinoff BB, Kozlowska H, Creighton AM, Allan WP, Thampatty P, Yalowich JC. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Mol Pharmacol 1997; 52:839-845.
37. Hershko C, Link G, Tzahor M, Kaltwasser JP, Athias P, Grynberg A, et al. Anthracycline cytoxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med 1993; 122:245-251.
38. Fisher GR, Gutierrez PL, Oldcorne MA, Patterson LH. NAD(P)H (quinone acceptor) oxidoreductase (DT-diaphorase)-mediated two-electron reduction of anthraquinone-based antitumor agents and generation of hydroxy radicals. Biochem Pharmacol 1992; 43:575-585.
39. Barranco SC. Cellular and molecular effects of adriamycin on dividing and nondividing cells. Pharmacol Ther 1984; 24:303-319.
40. 3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin. Cancer Res 1990; 50:2307-2310.
41. Meyers CE. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 1998; 25(suppl 10):10-14.
42. Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992; 84:1725-1730.
43. Hasinoff BB, Schroeder PE, Patel D. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol 2003; 64:670-678.
44. Schroeder PE, Jensen PB, Sehested M, Hofland KF, Langer SW, Hasinoff BB. Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother Pharmacol 2003; 52:167-174.
45. Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 2003; 63:6602-6606.